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Abstract
Objectives—To estimate the economic value of screening pregnant women for Staphylococcus
aureus carriage before cesarean delivery.
Study Design—Computer simulation model.
Methods—We used computer simulation to assess the cost-effectiveness, from the third-party
payer perspective, of routine screening for S aureus (and subsequent decolonization of carriers)
before planned cesarean delivery. Sensitivity analyses explored the effects of varying S aureus
colonization prevalence, decolonization treatment success rate (for the extent of the puerperal
period), and the laboratory technique (agar culture vs polymerase chain reaction [PCR]) utilized
for screening and pathogen identification from wound isolates.
Results—Pre-cesarean screening and decolonization were only cost-effective when agar was
used for both screening and wound cultures when the probability of decolonization success was
≥50% and colonization prevalence was ≥40%, or decolonization was ≥75% successful and
colonization prevalence was ≥20%. The intervention was never cost-effective using PCR-based
laboratory methods. The cost of agar versus PCR and their respective sensitivities and
specificities, as well as the probability of successful decolonization, were important drivers of the
economic and health impacts of preoperative screening and decolonization of pregnant women.
The number needed to screen ranged from 21 to 2294, depending on colonization prevalence,
laboratory techniques used, and the probability of successful decolonization.
Conclusions—Despite high rates of cesarean delivery, presurgical screening of pregnant women
for S aureus and decolonization of carriers is unlikely to be cost-effective under prevailing
epidemiologic circumstances.
Staphylococcus aureus surgical site infections (SSIs) are associated with substantial
morbidity among women who undergo cesarean delivery, resulting in increased
postoperative length of stay, increased risk of readmission, and high medical costs.1 The
increasing incidence of postsurgical wound infections has paralleled a rise in the cesarean
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delivery rate. As many as 20% of women who deliver by cesarean are affected by an SSI,
and S aureus is the causative agent implicated in 25% to 50% of puerperal infections.1–8
Up to 35% of Americans are chronic or intermittent carriers of S aureus, with higher rates
observed among individuals with risk factors for colonization such as healthcare exposure,
recent antibiotic use, immune system compromise, and chronic health conditions such as
diabetes and hepatitis.5,9–12 Previous studies have shown that preoperative S aureus
screening and subsequent decolonization of carriers may lessen rates of SSIs among other
surgical populations.13–17 These measures may be of benefit in the setting of planned
cesarean delivery, but formal studies to determine the safety and efficacy of this practice
have not yet concluded.18 The economic value of implementing this strategy among
pregnant women, who tend to be younger and healthier than many patients with healthcare-
associated S aureus infections, has also not been studied.
To address this issue, we developed a computer simulation model to estimate the cost-
effectiveness and health impact of routine preoperative S aureus screening and
decolonization for women undergoing planned cesarean delivery.
MATERIALS AND METHODS
This study was exempted by the University of Pittsburgh Institutional Review Board. Our
stochastic decision analytic model, developed using TreeAge Pro 2009 (TreeAge Software,
Williamstown, Massachusetts), addressed the decision of whether to screen women for S
aureus colonization and decolonize carriers before planned cesarean delivery. Analyses
assumed a third-party payer perspective (accounting for only the direct costs of illness) and
time horizon for outcomes equal to the duration of the puerperal period, or approximately 1
month postdelivery. The 1-month timeline was utilized as a reasonable average based on
clinical experience. Because wound infections vary in severity (some are minor, requiring
fewer than 28 days of home health treatment, and some are major, requiring 1–2 months of
treatment), we used 1 month as an average. The model assumed that the large majority of
the impact on the woman’s quality of life and costs would take place within this time period.
Figure 1 depicts the general structure of the model. At baseline, women were 27.1 years old
(the median age at pregnancy in the United States) and preparing to undergo a planned
cesarean delivery with standard antibiotic prophylaxis.19 Screening was assumed to occur
alongside testing for Group B streptococcus at routine 35- to 37-week prenatal visits. This
assumption was based on the rationale for Group B streptococcus screening at the same
gestational age; colonization with S aureus can be transient, so screening should be
conducted as close to delivery as possible to serve as a reliable proxy of colonization status
at that time.2,9
The probability of a woman screening positive was influenced by the S aureus colonization
prevalence and the sensitivity and specificity of the laboratory technique used, either agar
culture or polymerase chain reaction (PCR). All women with a positive test result, regardless
of true colonization status (eg, true and false positive), received a preoperative
decolonization regimen of twice-daily intranasal mupirocin ointment and daily
chlorhexidine gluconate washes for 5 days.15 This regimen is generally considered safe—
reported side effects are minor (eg, nasal itching and discomfort, skin irritation)—and
assumed not to result in a quality-adjusted life-year (QALY) decrement.15,16,20
When successful, decolonization was assumed to mitigate the risk of post-cesarean infection
for the duration of the puerperal period. Women colonized with S aureus were assumed to
be 3 to 5 times more likely to experience staphylococcal post-operative wound infection
than their noncolonized counterparts, consistent with studies among other surgical
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populations (likeliest value for colonized women: 9%, range: 4%–20%; likeliest value for
noncolonized women: 2.25%, range: 0.80%–6.67%).2,15,21–24
Women who experienced a post-cesarean wound infection received empiric antibiotic
treatment for methicillin-susceptible S aureus (MSSA) until laboratory results were
available. Identification of methicillin-resistant S aureus (MRSA) resulted in a transition to
MRSA-appropriate antibiotic coverage for 7 to 14 days, while MSSA infection was treated
with a 7-day course of antibiotics.25 Cesarean wound infection carried a risk of
hospitalization and wound-opening procedure in both the inpatient and outpatient settings,
and 50% of women who underwent a wound-opening procedure were assumed to receive
subsequent home healthcare.
Data inputs were derived from a variety of sources of various design and quality, including
large-scale national databases, prior studies, and literature review (where available); the
remainder were assumptions based on experience at Magee-Womens Hospital, a large,
university-based academic women’s hospital in Pittsburgh, Pennsylvania, that performs
approximately 10,000 deliveries per year (Table 1). Inpatient stay cost and duration data
came from the Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample, a
longitudinal database of inpatient hospital stay data maintained by the Agency for
Healthcare Research and Quality.26,27 Pharmaceutical costs were set equivalent to the
national wholesale price listed in the Red Book.28 Procedure and laboratory cost data were
based on the Centers for Medicare & Medicaid Services reimbursement algorithm National
Limitation Amount.29,30 A 3% discount rate was applied to all costs and utility values, as
recommended by the Panel on Cost-Effectiveness in Health and Medicine.37.
Healthy pregnant women accrued an age-adjusted 0.92 QALY per year of life and a
projected life expectancy QALY estimate of 43.96.38 Women who developed a wound
infection were ascribed a QALY weight of 0.6 for the duration of an inpatient stay, if any,
and 0.7 for treatment as an outpatient. Given the paucity of data available from studies of
pregnant women, these QALY values were drawn from a cost-effectiveness analysis of
appendectomy wounds and were likely conservative estimates of the detriment attributable
to a cesarean wound infection.31 QALY decrements were attributed for the duration of
antibiotic treatment, or 7 to 14 days for an MRSA infection and 7 days for an MSSA
infection. Infected wounds that required opening accrued an additional 7 days, and patients
who required home health treatment were ascribed 7 extra days of QALY decrements.
Each simulation run consisted of 1000 hypothetical pregnant women who proceeded through
the model 1000 times, for a total of 1 million outcomes per simulated scenario. The
incremental cost-effectiveness ratio (ICER) of each scenario was calculated using the
equation below, and results were interpreted in the context of 2 cost-effectiveness
thresholds: $50,000 per QALY and $100,000 per QALY.39
The number needed to screen (NNS), or the number of women who would need to be
screened to prevent 1 post-cesarean wound infection, regardless of true colonization status
or decolonization treatment rendered, was calculated as follows:
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Probabilistic sensitivity analyses simultaneously varied all parameters throughout the ranges
listed in Table 1. Additional sensitivity analyses explored key variables and those with the
greatest uncertainty/variability. We systematically explored the effect of varying S aureus
colonization prevalence from 1% to 50%, in order to capture the variation that may occur
based on geographic location, individual risk factors such as healthcare exposure or recent
antibiotic use, and body site swabbed (eg, anterior nares vs groin). The probability of
successful decolonization was varied across the range of 0% to 90% to account for factors
such as differing anatomical colonization site(s), decolonization regimen efficacy, local
antimicrobial resistance patterns, and patient compliance. The laboratory techniques used for
screening and wound isolate identification were also explored in the following combinations
(screening-wound isolate): agar-agar, PCR-agar, and PCR-PCR to account for variation in
the cost, availability, and turnaround time of these diagnostics. Finally, we varied the costs
associated with hospitalization (± $1000).
RESULTS
Table 2 presents ICER values (dollars per QALY) for a variety of colonization prevalence
and decolonization success rate scenarios. The combination of agar-based screening and
wound culture yielded the lowest ICER values across all decolonization success and
colonization prevalence scenarios. ICER values were driven by low incremental
effectiveness values; even when the incremental costs were low ($3), the gain in QALYs
due to screening were minute (range: 0.000001 to 0.00307) for all scenarios. When ICER
values below $50,000 to $100,000 per QALY were considered cost-effective, the
intervention was favorable when the probability of decolonization success was ≥50% and
the colonization prevalence was ≥40%, decolonization was ≥75% successful and
colonization prevalence was ≥20%, or the decolonization success rate was ≥90% and the
colonization prevalence was ≥20%. Exploratory analyses of colonization prevalence >50%
revealed that the testing scenario with a pairing of agar-agar became an economically
dominant intervention (less costly and more effective than no testing or decolonization)
when the probability of decolonization success was ≥75% and the colonization prevalence
was ≥95%, or the probability of successful decolonization was ≥90% and the colonization
prevalence was ≥75%. Varying the cost of hospitalization did not significantly change our
results. For the agar-agar pairing, ICER values were $5897 per QALY (hospitalization cost
+ $1000) and $13,220 (hospitalization cost – $1000) at a 90% decolonization success rate
and 50% colonization rate.
The use of PCR for screening and agar for wound cultures led to higher ICER values than
the agar-agar screening and culture combination. The intervention was never found to be
cost-effective (ICER values ≤$50,000 to $100,000 per QALY) when the probability of
decolonization success was ≤90% and the probability of colonization with S aureus was
≤50%. Exploratory analyses of colonization prevalence >50% revealed that the intervention
was cost-effective when the probability of decolonization success was ≥75% and
colonization prevalence was ≥80%, or decolonization was ≥90% effective and colonization
prevalence was ≥95%. The pairing of PCR and agar was never economically dominant. The
combination of PCR-PCR for screening and wound isolates yielded the highest ICER values
across all scenarios; this combination was never found to be cost-effective if the probability
of decolonization success was ≤90% and the S aureus colonization prevalence was ≤50%,
and was never economically dominant in any scenario, even if colonization prevalence was
100%.
The mean NNS to prevent 1 post-cesarean wound infection (regardless of true colonization
status or decolonization treatment rendered) for each of the 3 pairings of laboratory methods
is shown in Figure 2. A 25% probability of decolonization success was associated with the
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highest NNS values across all levels of S aureus colonization prevalence. The NNS was
2294 for the agar-agar pairing given 1% colonization prevalence and 25% probability of
successful decolonization, and an NNS of 72 was observed for the agar-agar pairing given
50% colonization prevalence and a 25% probability of decolonization success. NNS values
demonstrated similar decline for 50%, 75%, and 90% probabilities of successful
decolonization. When colonization prevalence was ≥25% and the probability of successful
decolonization was fixed at 25%, 50%, 75%, or 90%, the NNS was approximately equal for
all 3 pairings.
DISCUSSION
These results suggest that routine preoperative S aureus screening and decolonization of
carriers for women undergoing planned cesarean is rarely a cost-effective intervention, and
only for the pairing of agar-based testing and agar-based wound culture. In addition, the
intervention is unlikely to be cost saving given the current epidemiologic circumstances of S
aureus colonization in the United States. The prevalence of S aureus carriage among
pregnant women has been reported to range from 5% to 29%, well below the 75% (or
greater) value needed to yield cost savings in this study.5,9,40–42 The cost of implementing
routine surveillance and decolonization of S aureus carriers outweighs the potential cost
savings from preventing morbidity, mortality, and increased hospital lengths of stay
associated with post-cesarean S aureus wound infections.
There is some discordance in the rank order of the optimal pairing strategy when comparing
ICER with NNS under the same circumstances (eg, probability of successful decolonization
and colonization prevalence). This is likely a result of the cost difference between agar
culture and PCR laboratory techniques, and the respective predictive values of agar culture
and PCR for the detection of S aureus. Given the moderate S aureus colonization prevalence
and relatively low incidence of post-cesarean infection in this population, cost of the
intervention is a primary driver of the results. The impact of the higher sensitivity and
specificity of PCR versus agar is best seen in the NNS values. Because correct ascertainment
of colonization status is more likely with PCR-based screening, colonized women are more
likely to get potentially beneficial presurgical decolonization treatment and there is a low
probability that a presurgical decolonization regimen will be prescribed to a non-colonized
woman. As a result, PCR-based screening reduces the cost and risk of unnecessary
treatment, side effects, and the development of antimicrobial resistance.
Data on the short-term effectiveness of various decolonization regimens, especially for
pregnant women, are equivocal.15–17 There is a need for future studies, particularly well-
designed randomized controlled trials, to better establish the efficacy of various
decolonization regimens among this population. The assumption that pregnant women
colonized with S aureus are at an increased risk of infection is based on the increased risk of
S aureus infections seen among other surgical patients. The validity of this extension is
unknown given the paucity of relevant data in the literature; additional studies of the risk of
S aureus colonization (in the nares and other sites such as the perineum and vagina) on
postpartum and post-cesarean infection would be a valuable addition to the body of
knowledge.
Delivery by cesarean has become the most common major surgery among women in the
United States each year. The US cesarean delivery rate (both primary and repeat procedures)
has increased more than 50% since 1996 and reached an all-time high of 32.3% in 2008.43
Historically, cesarean rates have increased with increasing age, but in recent years the rate
has increased substantially across all maternal age and risk groups, race/ethnic groups,
gestational ages, and geographic locations.44 The rapidly increasing rate of cesarean
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delivery, coupled with the fact that it is major abdominal surgery, has spurred questions
about the clinical and nonmedical factors contributing to the upward trend.45 An operative
procedure of this magnitude is not without risk to mother and baby; cesarean deliveries have
been associated with increased rates of operative complications, maternal rehospitalization,
and neonatal intensive-care unit admission for neonates.45
Our analyses outlined the potential economic impact of implementing a routine pre-cesarean
screening and decolonization program under a variety of circumstances. This study may be
of interest to clinicians, infection control specialists, hospital administrators, and insurers
who make complex decisions regarding the finance and practice of clinical care. As with any
cost-effectiveness analysis, our findings are only intended to serve as informative evidence
for the decision-making process. A sound decision is based on multiple factors such as
clinical experience; budgetary constraints; competition for physical, personnel, and
monetary resources; and disease epidemiology.
Our study may have underestimated the potential benefit of implementing a screening and
decolonization strategy. Precesarean screening and decolonization could mitigate the risk of
developing S aureus mastitis, which affects 2% to 33% of breast-feeding women.7 It could
also limit transmission of S aureus from mothers to their newborns, thereby minimizing
infections in a vulnerable population with immature immune systems. Additionally, some
women may require a repeat surgical procedure and thus may benefit from the
decolonization intervention. Also, we limited our outcomes to the puerperal period;
however, some women may have impacts lasting longer than 1 month. We did not attempt to
quantify the impact of decreased S aureus colonization in the population or the subsequent
epidemiologic impact. Finally, routine surveillance could provide important data on the
epidemiology of S aureus among the population of pregnant women.
Overall, our study findings indicate that screening pregnant women for S aureus with
decolonization before cesarean delivery is not a cost-effective intervention under prevailing
epide-miologic circumstances, despite the increasing rate of delivery by cesarean. Future
studies are needed to ascertain the safety and efficacy of various decolonization regimens for
this population, as is delineation of the risk of postpartum and post-cesarean infection
attributable to S aureus colonization at different anatomical sites such as the nares, vagina,
and perineum.
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Take-Away Points
Screening pregnant women for Staphylococcus aureus before cesarean delivery is
unlikely to be cost-effective under currently prevailing epidemiologic circumstances in
the United States.
■ The results were similar for analyses with cost-effectiveness thresholds of
$50,000 per quality-adjusted life-year (QALY) and $100,000 per QALY
■ Additional studies are needed to ascertain the safety and efficacy of
decolonizing pregnant women, as well as the risk of post-cesarean infection
attributable to S aureus.
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Figure 1. General Model Structure
MSSA indicates methicillin-susceptible Staphylococcus aureus; OR, operating room; SSI,
surgical site infection; tx, treatment.
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Figure 2. Number Needed to Screen to Prevent 1 Post-cesarean Wound Infection
PCR indicates polymerase chain reaction.
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Table 1
Model Data Inputs
Variable
Distribution
Type
Mean,a Median,b
or Modec
Standard Deviation
or Range Reference
Patient characteristics
Age of pregnant women, y — 27.1b — 19
QALY value: inpatient treatment of wound infection — 0.60 — 31
QALY value: outpatient treatment of wound infection — 0.70 — 31
Costs, $
Laboratory
  Agar screening/wound culture — 12.34a 0.95 29
  PCR screening/wound culture — 50.27a 5.53 29
Pharmaceuticals
  Cephalexin (per day) γ 7.47a 5.71 28
  Chlorhexidine (full course) γ 6.44a 2.88 28
  Mupirocin (full course) γ 8.07a 1.38 28
  Sulfamethoxazole-trimethoprim (per day) γ 3.29a 1.27 28
  Unasyn (per day) γ 65.25a 14.80 28
  Vancomycin (per day) γ 31.49a 16.84 28
Hospitalization
  Maternal hospitalization for wound infection γ 6110.53a 394.47 26,27
Procedures and supplies
  Home health supplies (per week) γ 34.78a 6.96 Assumptiond
  Home health visitation (per week) γ 469.75a 93.91 Assumptiond
  Open wound incision in outpatient setting γ 50.41a 4.55 30
  Open wound incision in OR γ 735.18a 45.54 30
  Open wound incision on ward γ 74.89a 7.20 30
Duration, days
Antibiotic treatment for MRSA — 7–14 — 25
Antibiotic treatment for MSSA — 7 — 25
Empiric antibiotic treatment Δ 1.5 c 1.0–2.0 Assumptiond
Home health treatment Δ 28c 14–42 Assumptiond
Maternal hospitalization for wound infection γ 3.8a 0.1 26,27
Probability, %
Conditions and procedures
  Wound infection if S aureus colonized Δ 9 4–20 2,15,21–24
  Wound infection if not S aureus colonized Δ 2.25 0.8–6.67 2,15,21–24
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Variable
Distribution
Type
Mean,a Median,b
or Modec
Standard Deviation
or Range Reference
  Hospitalization (given wound infection) Δ 2.0c 1.5–2.5 32, Assumptiond
  Inpatient wound-opening procedure (given hospitalization) Δ 95c 91–99 Assumptiond
    Wound opening in OR Δ 15c 0–36 Assumptiond
    Wound opening on ward Δ 85c 64–1 Assumptiond
  Outpatient wound-opening procedure Δ 20 5–40 Assumptiond
  Home health after wound opening — 75 — Assumptiond
  Home health after outpatient wound opening — 25 — Assumptiond
Laboratory
Agar culture sensitivity Δ 90 95.5–100 33–36
Agar culture specificity Δ 95 97.5–100 33–36
PCR sensitivity Δ 97 98.125–100 33–36
PCR specificity Δ 95.5 98.34–100 33–36
Sensitivity analyses Values Source
Probability of colonization 1%–50% (by increments of 5%) Assumption
Probability of successful decolonization 25%, 50%, 75%, 90% Assumption
Laboratory technique (screening/wound isolate) Agar-agar, PCR-agar, PCR-PCR Assumption
MRSA indicates methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; OR, operating room; PCR,
polymerase chain reaction; QALY, quality-adjusted life-year.
a
Mean value.
b
Median value.
c
Mode value.
d
Assumption based on experience at Magee-Womens Hospital.
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